EphB6 Antibody ( FITC )

EphB6 Antibody Datasheet

EphB6 Antibody Product Information

• Immunogen: Recombinant Human EphB6 protein (Catalog#10197-H08H)
• Reagents: FITC-conjugated mouse monoclonal antibody
• Clone ID: 05
• Ig Type: Mouse IgG2b
• Concentration: 10 μl/Test, 0.1 mg/ml
• Formulation: Aqueous solution containing 0.5% BSA and 0.09% sodium azide
• Preparation: This antibody was produced from a hybridoma resulting from the fusion of a mouse myeloma with B cells obtained from a mouse immunized with purified, recombinant Human EphB6 (rh EphB6; Catalog#10197-H08H; NP_004436.1; Met 1-Ser 579) and conjugated with FITC under optimum conditions, the unreacted FITC was removed.

EphB6 Antibody Usage Guide

• Specificity: Human EphB6
• No cross-reactivity in ELISA with
  

  Human EphB4

  Human cell lysate (293 cell line)

• Flow Cytometry:
  

  Profile of anti-Human EphB6 reactivity on Jurkat cells analyzed by flow cytometry.

  Flow cytometry was performed on a BD FACSCalibur flow cytometry system

  Please refer to www.sinobiological.com/Flow-Cytometry-FACS-Protocols-a-750.html for technical protocols.

• Storage: This antibody is stable for 12 months from date of receipt when stored at 2℃-8℃. Protected from prolonged exposure to light. Do not freeze !
  Sodium azide is toxic to cells and should be disposed of properly. Flush with large volumes of water during disposal.

EphB6 Antibody Background

Ephrins are divided into the ephrin-A (EFNA) class and the ephrin-B (EFNB) class based on their structures and sequence relationships. Ephrin receptors make up the largest subgroup of the receptor tyrosine kinase (RTK) family, and EphB6 binding to ephrin-B ligands is a unique member in that its kinase domain contains several alterations in conserved amino acids and is catalytically inactive. It is indicated that activated by an Src family kinase, EphB6 can act as both positive and negative regulators in the process of cell adhesion and migration,The large family of Ephrin receptors and their ligands, the ephrins, mediate numerous developmental processes, particularly the establishment of regional pattern in the nervous system. Furthermore, the Eph receptors have been suggested to play important roles in tumor formation, prognosis, and possible gene-therapeutic approaches, and the reduction of EphB6 gene expression is associated with the progression of metastatic diseases.

References

1. Flanagan, J.G. et al., 1998, Annu. Rev. Neurosci. 21: 309-345.
2. Matsuoka, H. et al., 2005, J. Biol. Chem. 280: 29355-29363.
3. Holder, N. et al., 1999, Development. 126: 2033-2044.
4. Cheng, N. et al., 2002, Cytokine. Growth. Factor. Rev. 13: 75-85.
5. Hafner,C. et al., 2003, Int. J.Oncol. 23: 1553-1559.
6. Fox, B.P. et al., 2006, Biochem.Biophys.Res.Commun.340: 268-276.